CA Patent

CA2812034C — Methods for concomitant treatment of theophylline and febuxostat

Assigned to Takeda Pharmaceuticals USA Inc · Expires 2018-10-23 · 8y expired

What this patent protects

The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline with…

USPTO Abstract

The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline without resulting in theophylline toxicity to the patient and without substantial adjustments to the manufacturer's recommended dosage of theophylline.

Drugs covered by this patent

Patent Metadata

Patent number
CA2812034C
Jurisdiction
CA
Classification
—
Expires
2018-10-23
Drug substance claim
No
Drug product claim
No
Assignee
Takeda Pharmaceuticals USA Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.